[1]

Le Loarer F, Watson S, Pierron G, de Montpreville VT, Ballet S, et al. 2015. SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. Nature Genetics 47(10):1200−1205

doi: 10.1038/ng.3399
[2]

Ye W, An D, Ou WB. 2025. SMARCA4: Promises and challenges in the treatment of cancers. Cancer Letters 625:217811

doi: 10.1016/j.canlet.2025.217811
[3]

Mardinian K, Adashek JJ, Botta GP, Kato S, Kurzrock R. 2021. SMARCA4: implications of an altered chromatin-remodeling gene for cancer development and therapy. Molecular Cancer Therapeutics 20(12):2341−2351

doi: 10.1158/1535-7163.MCT-21-0433
[4]

Wang P, Song X, Cao D, Cui K, Wang J, et al. 2020. Oncogene-dependent function of BRG1 in hepatocarcinogenesis. Cell Death & Disease 11(2):91

doi: 10.1038/s41419-020-2289-3
[5]

Zhu PP, Li JH, Liu XL, Du HY, Su J, et al. 2022. Clinicopathological features of SMARCA4-deficient tumors. Chinese Journal of Pathology 51(8):792−798 (in Chinese)

doi: 10.3760/cma.j.cn112151-20220226-00131
[6]

Leitner K, Tsibulak I, Wieser V, Knoll K, Reimer D, et al. 2020. Clinical impact of EZH2 and its antagonist SMARCA4 in ovarian cancer. Scientific Reports 10(1):20412

doi: 10.1038/s41598-020-77532-x